To address the ethical challenges in big data health research we propose the concept of systemic oversight. This approach is based on six defining features (adaptivity, flexibility, monitoring, responsiveness, reflexivity, and inclusiveness) and aims at creating a common ground across the oversight pipeline of biomedical big data research. Current trends towards enhancing granularity of informed consent and specifying legal provisions to address informational privacy and discrimination concerns in data-driven health research are laudable. However, these solutions alone cannot have the desired impact unless oversight activities by different stakeholders acquire a common substantive orientation.
Get full access to this article
View all access options for this article.
References
1.
F. S.Collins and H.Varmus, “A New Initiative on Precision Medicine,”New England Journal of Medicine372, no. 9 (2015): 793–795; E. Elenko, L. Underwood, and D. Zohar, “Defining Digital Medicine,” Nature Biotechnology 33, no. 5 (2015): 456–461; S. Hawgood, I. G. Hook-Barnard, T. C. O'Brien, and K. R. Yamamoto, “Precision Medicine: Beyond the Inflection Point,” Science Translational Medicine 7, no. 300 (2015): 300ps17; A. Blasimme and E. Vayena, “‘Tailored-to-You’: Public Engagement and the Political Legitimation of Precision Medicine,” Perspectives in Biology and Medicine 59, no. 2 (2017): 172–188.
2.
National Research Council, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (Washington, D.C.: National Academies Press, 2011).
3.
Blasimme and Vayena, supra note 1; A.Blasimme and E.Vayena, “Becoming Partners, Retaining Autonomy: Ethical Considerations on the Development of Precision Medicine,”BMC Medical Ethics17, no. 1 (2016): 67.
4.
J. S.Brownstein, C. C.Freifeld, and L. C.Madoff, “Digital Disease Detection — Harnessing the Web for Public Health Surveillance,”New England Journal of Medicine360, no. 21 (2009): 2153–2157; M. Salathé et al., “Digital Epidemiology,” PLOS Computational Biology 8, no. 7 (2012): e1002616; E. Vayena, M. Salathé, L. C. Madoff, J. S. Brownstein, “Ethical Challenges of Big Data in Public Health,” PLoS Computational Biology 11, no. 2 (2015): e1003904, doi:10.1371/journal.pcbi.1003904; M. J. Khoury, M. F. Iademarco, and W. T. Riley, “Precision Public Health for the Era of Precision Medicine,” American Journal of Preventive Medicine 50, no. 3 (2016): 398–401; A. Flahault, A. Geissbuhler, I. Guessous, P. Guérin, I. Bolon, M. Salathé, and G. Escher, “Precision Global Health in the Digital Age,” Swiss Medical Weekly 147 (2017): w14423.
5.
A.Blasimme, T.Haüserman, A.Adjekum, and E.Vayena, “Digital Health: Meeting the Ethical and Policy Challenges,”Swiss Medical Weekly (in press); E. Underwood and D. Zohar, “Defining Digital Medicine,” Nature Biotechnology 33, no. 5 (2015): 456–461.
6.
L.Floridi, ed., The Onlife Manifesto: Being Human in a Hyperconnected Era (New York: Springer, 2014): at 7.
7.
World Health Organization, The Health Data Ecosystem and Big Data, available at <http://www.who.int/ehealth/resources/ecosystem/en/> (last visited January 24, 2018); E. Vayena, J. Dzenowagis, J.S. Brownstein, and A. Sheikh, “Policy Implications of Big Data in the Health Sector,” Bulletin of the World Health Organization 96, no. 1 (2018): 66-68.
8.
S. H.Jain, B. W.Powers, J. B.Hawkins, and J. S.Brown-stein, “The Digital Phenotype,”Nature Biotechnology33, no. 5 (2015): 462–463; E. Vayena and U. Gasser, “Strictly Biomedical? Sketching the Ethics of the Big Data Ecosystem in Biomedicine,” in B. D. Mittelstadt and L. Floridi, eds., The Ethics of Biomedical Big Data (Cham, Switzerland: Springer International Publishing, 2016): 17-39.
9.
C. C.Freifeld, J. S.Brownstein, C. M.Menone, W.Bao, R.Filice, and T.Kass-Hout, “Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter,”Drug Safety37, no. 5 (2014): 343–350.
10.
D.O'Brien, J.Ulman, M.Altman, U.Gasser, M.Bar-Sinai, K.Nissim, S.Vadhan, M. J.Wocik, and A.Wood, “Integrating Approaches to Privacy Across the Research Lifecycle: When Is Information Purely Public?”Berkman Center Research Publication, Paper no. 2015-7 (2015), available at <https://papers.ssrn.com/abstract=2586158> (last visited December 27, 2017).
I. G.Cohen, R.Amarasingham, A.Shah, B.Xie, and B.Lo, “The Legal And Ethical Concerns That Arise From Using Complex Predictive Analytics In Health Care,”Health Affairs33, no. 7 (2014): 1139–1147; W. Nicholson Price II, “Black-Box Medicine,” Harvard Journal of Law & Technology 28, no. 2 (2015): 419-467.
D.Nafus, ed., Quantified: Biosensing Technologies in Everyday Life (Cambridge, MA: MIT Press, 2016): at ix.
15.
J. L.Roberts, S.Pereira, and A. L.McGuire, “Should You Profit from Your Genome?”Nature Biotechnology35, no. 1 (2017): 18–20.
16.
G. M.Weber, K. D.Mandl, and I. S.Kohane, “Finding the Missing Link for Big Biomedical Data,”JAMA311, no. 24 (2014): 2479–2480.
17.
E.Hafen, “Midata Cooperatives — Citizen-Controlled Use of Health Data Is a Prerequisite for Big Data Analysis, Economic Success and a Democratization of the Personal Data Economy,”Abstract presented at 9th European Congress on Tropical Medicine and International Health, September 6-10, 2015, Basel, Switzerland, in Tropical Medicine & International Health20, Suppl. 1 (2015): 129.
18.
E.Vayena, A.Mastroianni, and J.Kahn, “Caught in the Web: Informed Consent for Online Health Research,”Science Translational Medicine5, no. 173 (2013): 173fs6.
19.
E. C.Hayden, “A Broken Contract,”Nature486, no. 7403 (2012): 312–314.
20.
G. E.Henderson, “Is Informed Consent Broken?”American Journal of the Medical Sciences342, no. 4 (2011): 267–272.
B. S.Elger and A. L.Caplan, “Consent and Anonymization in Research Involving Biobanks: Differing Terms and Norms Present Serious Barriers to an International Framework,”EMBO Reports7, no. 7 (2006): 661-666.
A.Blasimme, C.Moret, S. A.Hurst, and E.Vayena, “Informed Consent and the Disclosure of Clinical Results to Research Participants,”American Journal of Bioethics17, no. 7 (2017): 58-60.
27.
C.Grady, L.Eckstein, B.Berkman, D.Brock, R.Cook-Deegan, S. M.Fullerton, H.Greely, M. G.Hansson, S.Hull, B.Lo, R.Pentz, L.Rodriguez, C.Weil, B. S.Wilfond, and D.Wendler, “Broad Consent for Research With Biological Samples: Workshop Conclusions,”American Journal of Bioethics15, no. 9 (2015): 34–42.
28.
D.Wendler and E.Emanuel, “The Debate over Research on Stored Biological Samples: What Do Sources Think?”Archives of Internal Medicine162, no. 13 (2002): 1457–1462.
29.
D.Wendler, “Broad versus Blanket Consent for Research with Human Biological Samples,”Hastings Center Report43, no. 5 (2013): 3-4; T. Tomlinson, “Respecting Donors to Biobank Research,” Hastings Center Report 43, no. 1 (2013): 41–47.
30.
J. E.Lunshof, R.Chadwick, D. B.Vorhaus, and G. M.Church, “From Genetic Privacy to Open Consent,”Nature Reviews Genetics9, no. 5 (2008): 406–411.
31.
See Vayena et al., supra note 18.
32.
V.Árnason, “Coding and Consent: Moral Challenges of the Database Project in Iceland,”Bioethics18, no. 1 (2004): 27–49; B. Hofmann, “Broadening Consent — and Diluting Ethics?,” Journal of Medical Ethics 35, no. 2 (2009): 125–129; J. R. Karlsen, J. H. Solbakk, and S. Holm, “Ethical Endgames: Broad Consent for Narrow Interests; Open Consent for Closed Minds,” Cambridge Quarterly of Healthcare Ethics 20, no. 4 (2011): 572–583.
33.
G.Helgesson, “In Defense of Broad Consent,”Cambridge Quarterly of Healthcare Ethics21, no. 1 (2012): 40–50.
34.
Food and Drugs Administration, “Use of Electronic Informed Consent: Questions and Answers. Guidance for Institutional Review Boards, Investigators and Sponsors”available at <https://www.fda.gov/downloads/drugs/guidances/ucm436811.pdf> (last visited January 24, 2018); J. Kaye, E. A. Whitley, D. Lund, M. Morrison, H. Teare, and K. Melham, “Dynamic Consent: A Patient Interface for Twenty-First Century Research Networks,” European Journal of Human Genetics 23, no. 2 (2015): 141-146.
35.
F. H.Cate and V.Mayer-Schönberger, “Notice and Consent in a World of Big Data,”International Data Privacy Law3, no. 2 (2013): 67–73.
36.
See Vayena et al., supra note 18.
37.
See Nafus, supra note 14.
38.
J. P.Kahn, E.Vayena, and A. C.Mastroianni, “Opinion: Learning as We Go: Lessons from the Publication of Facebook's Social-Computing Research,”Proceedings of the National Academy of Sciences111, no. 38 (2014): 13677–13679.
39.
E.Vayena and A.Blasimme, “Biomedical Big Data: New Models of Control over Access, Use and Governance,”Journal of Bioethical Inquiry14, no. 4 (2017): 1-13.
40.
Blasimme et al., supra note 26; A.Blassime, A.Soulier, S.Julia, S.Leonard, and A.Cambon-Thomsen, “Disclosing Results to Genomic Research Participants: Differences That Matter,”American Journal of Bioethics12, no. 10 (2012): 20-22; E. Vayena and J. Tasioulas, “Genetic Incidental Findings: Autonomy Regained?” Genetics in Medicine 15, no. 11 (2013): 868-870.
41.
V.Anastasova, A.Blasimme, S.Julia, and A.Cambon-Thomsen, “Genomic Incidental Findings: Reducing the Burden to Be Fair,”American Journal of Bioethics13, no. 2 (2013): 52-54.
42.
T.Caulfield, R. E. G.Upshur, and A.Daar, “DNA Databanks and Consent: A Suggested Policy Option Involving an Authorization Model,”BMC Medical Ethics4, no. 1 (2003): E1.
43.
E. M.Bunnik, A.Cecile, J. W.Janssens, and M. H. N.Schermer, “A Tiered-Layered-Staged Model for Informed Consent in Personal Genome Testing,”European Journal of Human Genetics21, no. 6 (2013): 596–601.
44.
A. L.McGuire and L. M.Beskow, “Informed Consent in Genomics and Genetic Research,”Annual Review of Genomics and Human Genetics11 (2010): 361–381.
45.
J.Kaye, E. A.Whitley, D.Lund, M.Morrison, H.Teare, and K.Melham, “Dynamic Consent: A Patient Interface for Twenty-First Century Research Networks,”European Journal of Human Genetics23, no. 2 (2015): 141–146; I. Budin-Ljøsne, H. J. A. Teare, J. Kaye, S. Beck, H. B. Bentzen, L. Caenazzo, C. Collett, F. D. Abramo, H. Felzmann, T. Finlay, M. K. Javaid, E. Jones, V. Katic, A. Simpson, and D. Mascalzoni, “Dynamic Consent: A Potential Solution to Some of the Challenges of Modern Biomedical Research,” BMC Medical Ethics 18, no. 1 (2017): 4
46.
See Kahn et al., supra note 38.
47.
K. H.Jones, G.Laurie, L.Stevens, C.Dobbs, D. V.Ford, and N.Lea, “The Other Side of the Coin: Harm due to the Non-Use of Health-Related Data,”International Journal of Medical Informatics97, no. 1 (2017): 43–51.
48.
See Kahn et al., supra note 38.
49.
J.Sugarman, “Examining Provisions Related to Consent in the Revised Common Rule,”American Journal of Bioethics17, no. 7 (2017): 22–26.
50.
“Governance” has been defined by the Club of Rome as “the command mechanism of a social system and its actions that endeavor to provide security, prosperity, coherence, order and continuity to the system.… Taken broadly, the concept of governance should not be restricted to the national and international systems but should be used in relation to regional, provincial and local governments as well as to other social systems.” A.King and B.Schneider, The First Global Revolution. A Report of the Council of the Club of Rome (New York: Pantheon Books, 1991): at 114. Other definitions aptly tone down the hierarchical and directive sense conveyed by the expression “command mechanisms” and emphasize — as we also propose — the centrality of steering and control mechanisms to the idea of governance. See, e.g., J. N. Rosenau, “Governance in the Twenty-First Century,” Global Governance 1, no. 1 (1995): 13–43.
51.
P.Macnaghten, M. B.Kearnes, and B.Wynne, “Nanotechnology, Governance, and Public Deliberation: What Role for the Social Sciences?”Science Communication27, no. 2 (2005): 268–291.
52.
G.Laurie, “Reflexive Governance in Biobanking: On the Value of Policy Led Approaches and the Need to Recognise the Limits of Law,”Human Genetics130, no. 3 (2011): 347-356.
F.Pasquale, The Black Box Society: The Secret Algorithms That Control Money and Information (Cambridge: Harvard University Press, 2015): at 51; Price, supra note 12.
55.
P. M.Macnaghten, M. B.Kearnes, and B.Wynne, “Nanotechnology, Governance, and Public Deliberation,”Science Communication27, no. 2 (2005): 268-291.
56.
J.-P.Voß and B.Bornemann, “The Politics of Reflexive Governance: Challenges for Designing Adaptive Management and Transition Management,”Ecology and Society16, no. 2 (2011): 9.
57.
C. M.Hendriks and J.Grin, “Contextualizing Reflexive Governance: The Politics of Dutch Transitions to Sustainability,”Journal of Environmental Policy & Planning9, no. 3 (2007): 333–350.
58.
D.Collingridge, The Social Control of Technology (New York: St. Martin's Press, 1980): at 47.
59.
R. A. W.Rhodes, “The New Governance: Governing without Government,”Political Studies44, no. 4 (1996): 652–667; J. Scott and D. M. Trubek, “Mind the Gap: Law and New Approaches to Governance in the European Union,” European Law Journal 8, no. 1 (2002): 1–18.
60.
P.Macnaghten, M. B.Kearnes, and B.Wynne, “Nanotechnology, Governance and Public Deliberation: What Role for the Social Sciences?”Science Communication27, no. 2 (2005): 268-291.
61.
G.Ramachandran, S. M.Wolf, J.Paradise, J.Kuzma, R.Hall, E.Kokkoli, and L.Fatehi, “Recommendations for Oversight of Nanobiotechnology: Dynamic Oversight for Complex and Convergent Technology,”Journal of Nanoparticle Research13, no. 4 (2011): 1345–1371.
62.
Voß and Bornemann, supra note 56.
63.
A.Rip, J.Schot, and T. J.Misa, “Constructive Technology Assessment: A New Paradigm for Managing Technology in Society”, in A.Rip, J.Schot, and T. J.Misa (eds.), Managing Technology in Society. The Approach of Constructive Technology Assessment (New York: Pinter Publishers, 1995): 1-14; D. H. Guston and D. Sarewitz, “Real-Time Technology Assessment,” Technology in Society 24, nos. 1–2 (2002): 93–109; J. Grin and H. van de Graaf, “Technology Assessment as Learning,” Science, Technology & Human Values 21, no. 1 (1996): 72–99; A. Genus, “Rethinking Constructive Technology Assessment as Democratic, Reflective, Discourse,” Technological Forecasting and Social Change 73, no. 1 (2006): 13–26.
64.
Voß and Bornemann, supra note 56.
65.
J.Stilgoe, R.Owen, and P.Macnaghten, “Developing a Framework for Responsible Innovation,”Research Policy42, no. 9 (2013): 1568–1580.
66.
K. C.O'Doherty, M. M.Burgess, K.Edwards, R. P.Gallagher, A. K.Hawkins, J.Kaye, V.McCaffrey, and D. E.Winckoff, “From Consent to Institutions: Designing Adaptive Governance for Genomic Biobanks,”Social Science & Medicine73, no. 3 (2011): 367–374.
67.
See Sekeres and Gilligan, supra note 21.
68.
S. B.Garrett, D.Dohan, and B. A.Koenig, “Linking Broad Consent to Biobank Governance: Support From a Deliberative Public Engagement in California,”American Journal of Bioethics15, no. 9 (2015): 56–57; E. Vayena, R. Brownsword, S. J. Edwards, B. Greshake, J. P. Kahn, N. Ladher, J. Montgomery, D. O'Connor, M. P. Richards, A. Rid, M. Sheehan, P Wicks, and J Tasioulas, “Research Led by Participants: A New Social Contract for a New Kind of Research,” Journal of Medical Ethics 42, no. 4 (2016): 216–219.
69.
B. J.Evans, “Barbarians at the Gate: Consumer-Driven Health Data Commons and the Transformation of Citizen Science,”American Journal of Law & Medicine42, no. 4 (2016): 651-658; B. J. Evans, “Power to the People: Data Citizens in the Age of Precision Medicine,” Vanderbilt Journal of Entertainment & Technology Law 19, no. 2 (2017): 243-265.
70.
M. G.Hansson, J.Dillner, C. R.Bartram, J. A.Carlson, and G.Helgesson, “Should Donors Be Allowed to Give Broad Consent to Future Biobank Research?”The Lancet Oncology7, no. 3 (2006): 266–269.
71.
M.Shabani, B. M.Knoppers, and P.Borry, “From the Principles of Genomic Data Sharing to the Practices of Data Access Committees,”EMBO Molecular Medicine7, no. 5 (2015): 507–509.
72.
C.Grady, L.Eckstein, B.Berkman, D.Brock, R.Cook-Deegan, S. M.Fullerton, H.Greely, et al., “Broad Consent for Research With Biological Samples: Workshop Conclusions,”American Journal of Bioethics15, no. 9 (2015): 34–42.
73.
European General Data Protection Regulation, available at <https://www.eugdpr.org/> (last visited January 24, 2018).
E.Vayena, U.Gasser, A.Wood, D. R.O'Brien, and M.Altman, “Elements of a New Ethical Framework for Big Data Research,”Washington & Lee Law Review72, no. 3 (2016): 420-441, available at <http://scholarlycommons.law.wlu.edu/wlulr-online/vol72/iss3/5/> (last visited January 24, 2018).
